Background. Most cardiovascular implantable electronic device (CIED) recipients are elderly, have multiple comorbid conditions, and are at increased risk of CIED infection (CIEDI). Current guidelines recommend complete device removal in patients with CIEDI to prevent relapse and mortality. However, comorbidities or other factors may preclude device removal, thus prompting a nonsurgical approach that includes chronic antibiotic suppression (CAS). There are limited data on outcomes of patients receiving CAS for CIEDI.
Cardiovascular implantable electronic devices (CIEDs) have played a crucial role in the management of heart disease ever since the first permanent pacemaker (PPM) implant in 1958 [1] . CIED technology has since evolved to include implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) [2] . Approximately 70% of CIED recipients are aged >65 years, and more than 75% have 1 or more comorbidities, including hypertension, diabetes, renal failure, and chronic pulmonary disease [3, 4] .
Given the prevalence of comorbidities that predispose to infectious complications, hospitalizations for CIED infections (CIEDI) have increased (2.8-fold for PPMs and 6.0-fold for ICDs) [5] . Most PPM and ICD infections are due to coagulase-negative staphylococci (42%) and oxacillin-susceptible Staphylococcus aureus (25%). Less common pathogens include gram-negative bacilli (9%), polymicrobial (7%), or oxacillin-resistant S. aureus (4%) [6] . These organisms commonly cause pocket infection, which may extend to the cardiovascular portion of the CIED, leading to bacteremia and/or endocarditis [2] .
In 2003 and 2010, the American Heart Association (AHA) issued scientific statements regarding antibiotic therapy, indications for complete device removal, and timing of reimplantation of a new CIED. The AHA guidelines state that complete removal of all hardware is recommended for all patients with established CIEDI, as infection relapse rates are high with retained hardware. Percutaneous lead extraction is the preferred method of removal, but surgical removal may be necessary if percutaneous removal is unsuccessful or if lead vegetations are greater than 2 cm in diameter [2] .
Unfortunately, some patients may not be candidates for device removal due to multiple comorbidities, limited life expectancy, or personal preference. If these patients clinically improve with initial antimicrobial therapy and demonstrate clearance of bacteremia, if present, then they may be candidates for chronic antimicrobial suppression (CAS). However, there is a paucity of data regarding optimal antimicrobial regimens, infection relapse and mortality rates, and other outcomes. Potential drawbacks to CAS include risk for CIEDI cardiac-related infectious complications, antimicrobial adverse effects, selection of resistant pathogens, patient noncompliance, and financial expense [2] . Our goal in this study was to retrospectively assess outcomes of CIEDI managed without device removal and with CAS.
METHODS
This is a retrospective review of patients identified from the electronic medical record and an existing institutional database, which has accumulated a list of CIEDI cases since 1990. The electronic medical record was searched using the Advanced Cohort Explorer, which is our institution's data retrieval software. Search terms included cardiac, cardiovascular, device, pacemaker, implant, defibrillator, suppression, and the following International Classification of Diseases (ICD) codes: 996.61 (ICD-9, infection and inflammatory reaction due to cardiac device, implant, and graft) and T82.7XXA (ICD-10, infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts, initial encounter).
Inclusion criteria included age >18 years, diagnosis of CIEDI between 1 January 2005 and 1 January 2015, retention of CIED, recommendation for CAS, and Minnesota Research Authorization on file. Exclusion criteria included lack of research authorization and diagnosis of endocarditis that was not associated with CIED. This study did not involve direct contact with the participants. A Health Insurance Portability and Accountability Act (HIPAA) and informed consent waivers were obtained from our institutional review board. Only persons with appropriate authorization had access to participants' records for the purpose of the study, and patient confidentiality was maintained.
Between 2005 and 2015, 660 patients were screened, and 48 CIEDI cases were managed with parenteral antibiotic treatment followed by a recommendation for CAS, which was defined as continuation of antibiotics for longer than 8 weeks after initial CIEDI diagnosis. Primary outcomes were infection relapse and mortality at longest follow-up. Other variables included comorbidities, specific type of CIED (i.e., PPM, ICD, or CRT), number and age of leads, date of implant, date of diagnosis of CIEDI, clinical presentation, reason for retention of infected CIED, presence of other prostheses, attempted procedures, echocardiography results, type and duration of antibiotic therapy, presence of bacteremia, microbiology, antibiotic adverse reactions, and hospital length of stay. Demographic factors included age, gender, and ethnicity.
Descriptive analysis was performed using JMP10.0.0. Estimates of frequencies were calculated for categorical variables and of means and medians for continuous variables. Survival analysis was performed using Kaplan-Meier curves and log-rank tests. The Cox proportional hazards model was used to identify risk factors associated with worse overall survival.
RESULTS

Baseline Characteristics
Among 48 CIEDI cases, the median age was 78 years with an interquartile range (Q1-Q3) of 65.25-82.75 years. Seventythree percent (35/48) were male, and 88% (42/48) were white; 48% (23/48) of cases had PPMs, 38% (18/48) had ICDs, and 14% (7/48) had CRTs ( Table 1) .
The most common indications for initial implantation of a CIED were bradyarrhythmias (52%, 25/48), congestive heart failure or cardiomyopathy (33%, 16/48), ventricular tachycardia or fibrillation (25%, 12/48), and atrial fibrillation (25%, 12/48). Some patients had more than 1 indication for implantation. The majority (54%, 26/48) had 2 implanted leads. The median age of the oldest lead at the time of CIEDI diagnosis was 5.7 years (Q1-Q3 = 2.0-10.5 years). The median time from initial CIED implant to diagnosis of CIEDI was 2.3 years (Q1-Q3 = 0.8-3.8 years)
The most common clinical presentations of CIEDI were fever, chills, or sweats (63%, 30/48); respiratory complaints, such as dyspnea or cough (35%, 17/48); and fatigue (27%, 13/48). Only 10% (5/48) presented with signs of pocket infection, such as erythema or purulence. Patients had a median of 8 comorbidities (Q1-Q3 = 7-10), and the median Charlson comorbidity index (CCI) was 4 (Q1-Q3 = 3-6). The most common comorbidities were arrhythmias (92%, 44/48), ischemic heart disease (75%, 36/48), valvular heart disease (54%, 26/48), and hypertension (52%, 25/48). A total of 54% (26/48) had other intracardiac prostheses, such as valve replacements, and 23% (11/48) had an intravascular catheter, such as hemodialysis or peripherally inserted central catheters. None of them underwent attempted extractions of devices at outside institutions prior to presentation at our facility.
Clinical Outcomes
None of the 48 patients underwent attempted device removal at our institution during their initial hospitalization for CIEDI and, therefore, were included in the sample of CAS-eligible patients. Eighty-three percent (40/48) of patients had comorbidities or high surgical risk documented as the reason for conservative management; 10% (5/48) declined surgical extraction due to personal preference for a nonoperative approach. The remaining 6% (3/48) of cases did not have a reason for declining surgical extraction. The median duration of hospitalization was 9 days (Q1-Q3 = 6-18 days).
Ninety-two percent (44/48) of patients underwent transesophageal echocardiography (TEE), and 61% (27/44) had echocardiographic findings that included mobile masses or vegetations on leads or valves, which were suspicious for endocarditis. Four patients did not have a TEE as these patients had evidence of pocket infection only and had negative blood cultures.
Blood cultures were positive in 88% (42/48) of patients. Organisms included coagulase-negative staphylococci (21%, 10/48), methicillin-sensitive S. aureus (19%, 9/48), Enterococcus species (17%, 8/48), Streptococcus species (15%, 7/48), methicillin-resistant S. aureus (13%, 6/48), polymicrobial (6%, 3/48), culture-negative (4%, 2/48), Klebsiella pneumoniae (2%, 1/48), Serratia marcescens (2%, 1/48), and Pseudomonas aeruginosa (2%, 1/48). The median duration of parenteral antibiotic treatment for initial CIEDI was 28 days (Q1-Q3 = 20.25-42 days). Patients initiated CAS the day after completion of parenteral antibiotics.
Survival Analysis
A Kaplan-Meier curve for overall survival is shown in Figure 1 . Eight percent (4/48) of patients expired during the index hospitalization, and 92% (44/48) survived past discharge. At 1 month after dismissal, another 8 patients had died, thus 25% (12/48) died, of whom 67% (8/12) had staphylococcal infections. For these 12 patients, 11 had not yet started CAS and were therefore considered non-CAS recipients. Estimated median overall survival was 1.43 years (95% confidence interval [CI], 0.27-2.14). Estimated overall survival at 1 year using the Kaplan-Meier method was 50.3%.
Given a median CCI of 4, patients were divided into those with a CCI of 0-3 and those with a CCI ≥4. Analysis with the Cox proportional hazards model revealed that patients with a CCI ≥4 had significantly worse overall survival (hazard ratio, 2.22; 95% CI, 1.01-5.56; P = .046) compared to those with a CCI of 0-3 ( Table 2 ). The Kaplan-Meier curve for overall survival, grouped by CCI, is shown in Figure 2 . There was a trend toward worse survival in patients with a CCI ≥4 vs those with CCI of 0-3 (estimated median survival was 0.45 years vs 1.51 years; P = .055). Estimated overall survival was not significantly different between patients with staphylococcal vs nonstaphylococcal infections (median survival 0.56 vs 1.77 years; P = .2682).
There were 21 deaths at 1 year after hospital dismissal; however, by the last available follow-up (10 years by April 2016), more deaths had occurred. By the conclusion of data analysis at 10 years (median follow-up time 169.5 days, range 7-3649 days), 34 of the original 48 patients (71%) had expired. For these 34 patients, 24% (8/34) of deaths were attributed to the CIEDI, of which 63% (5/8) were due to sepsis, 13% (1/8) due to respiratory failure, and 25% (2/8) due to unknown causes. For the remaining 26 patients whose deaths were not attributed to CIEDI, causes of death included myocardial 
CAS and Relapse
Of the 48 original patients, 1 of the 12 patients who died within 1 month after hospitalization had initiated CAS prior to death. Including that one patient and the remaining patients, there were 37 who initiated CAS and were evaluable for CAS; 23% (11/48) did not initiate CAS due to early death. In the 37 patients who did initiate CAS, the following agents were used: 22% (8/37) penicillin G or VK, 22% trimethoprim-sulfamethoxazole (8/37), 22% amoxicillin (8/37), 14% (5/37) minocycline, 14% cephalexin (5/37), 3% (1/37) dicloxacillin, 3% (1/37) cefadroxil, and 3% (1/37) cefpodoxime. Figure 3 illustrates the number of patients who expired or were lost to follow-up at various time points. Of the 37 patients who initiated CAS, 3 were lost to follow-up within the first month after hospital dismissal, and 1 patient who initiated CAS expired within the first month as well. The remaining 33 patients were monitored for adverse reactions while on CAS. Eighteen percent (6/33) reported adverse reactions while receiving CAS, which included rash (9%, 3/33), Clostridium difficile infection (6%, 2/33), and pancreatitis (3%, 1/33). Two patients switched CAS agents due to rash, 1 underwent desensitization due to rash, 1 switched CAS agent due to pancreatitis, and 1 discontinued CAS due to C. difficile infection. One continued CAS despite C. difficile infection.
Given that 1 of the 34 patients who initiated CAS expired within 1 month of hospital dismissal, 33 of the original 48 patients were monitored for signs of infection relapse over the following 1 year. Eighteen percent (6/33) developed CIEDI relapse, and all 6 were treated with alternate CAS agents. Of these 6 patients, 33% (2/6) subsequently underwent extraction due to relapse. Of the 2 patients who underwent extraction, 1 was alive after 1 year and the other expired due to CIEDIrelated sepsis and multiorgan failure.
DISCUSSION
The patients with CIEDI who did not undergo device removal in our investigation were elderly (median age, 78 years; range, 34-92 years) and had multiple comorbidities (median CCI = 4). Cardiac device retention was associated with a high rate of CIEDI relapse (18%, 6/33) and mortality (44%, 21/48) at 1 year of follow-up. The high risk of device removal should be weighed against the high risks of mortality and relapse. There are few studies that have examined outcomes in patients with CIEDI treated conservatively and managed with CAS. In 2001, a retrospective study assessed outcomes in 51 patients treated with CAS for various cardiovascular device-related infections. Sixty-three percent of cases involved gram-positive cocci, and beta-lactams were the most frequently (39.2%) used antimicrobial. CAS duration ranged from 3 months to 10 years.
Three of 41 (7.32%) patients developed signs of relapsing infection upon follow-up. Three other patients reported medication-related adverse effects. The study concluded that CAS was well tolerated and efficacious in preventing relapse. Despite these encouraging results, the majority of patients had vascular graft infections (30 of 51 patients) and there were only 5 cases of CIEDI [7] . There have been a few case reports and series documenting successful medical management of pacemaker-associated sepsis, endocarditis, or infected ICDs [8] [9] [10] [11] . However, larger studies showed less promising results. A 1993 study on sustained bacteremia in 26 patients with a permanent endocardial pacemaker showed that cure was not achieved in 7 cases when the wire was not withdrawn [12] .
Other published series have noted that attempts to treat CIEDI with antibiotics alone were unsuccessful in 87%-98% of patients [13] . In 2003, a prospective cohort study was done on 31 patients with pacemaker or ICD endocarditis. Seven patients were treated with antimicrobials alone due to patient preference, comorbid conditions, or absence of vegetations on echocardiography. All 7 patients (100%) had relapses of endocarditis, and 1 patient died. It was not specified whether patients were given CAS [14] . In a 2004 study on 38 patients with pacemaker endocarditis, 16 patients were treated with medical therapy alone, and 13 (81%) of these patients had signs of infection at follow-up. Only 1 patient was given lifelong antimicrobial suppression [15] .
Our study was limited by its small sample size (n = 48) and a population consisting predominantly of males (73%, 35/48) and whites (88%, 42/48), thus limiting the generalizability of our results. However, CAS was effective in some patients (eg, 20 patients alive at 1 year) in our study and may be the only option available for patients deemed to be too high-risk for device removal.
Last, we theorize that there would be a higher mortality rate for patients with staphylococcal CIEDI due to staphylococci biofilm formation on the CIED surface, rendering them resistant to antibiotics [16] . However, our study did not show a significant difference in overall survival between staphylococcal infections and other microbial. This is most likely due to our sample size, and further studies in a larger, more diverse population would be needed to confirm this finding.
In conclusion, our study demonstrates that device retention in patients with CIEDI was associated with a high rate of mortality and an increased rate of relapse at follow-up 1 year later. Although device removal is optimal, it may be deemed too high-risk in a select group of patients, and thus, consideration of CAS is warranted. Further studies are needed to better define the optimal subpopulation that would most benefit from CAS.
